ZLAB

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2021 Results - Earnings Call Transcript

Zai Lab Announces First Quarter 2021 Financial Results